Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib in NF2-mutated Tumors (MATCH Subprotocol U)
NCT04439331Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), hematopoietic and lymphoid cell neoplasm, sponsored by National Cancer Institute. Started Nov 2015; status: active, not recruiting.
02
Drugs
defactinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)hematopoietic and lymphoid cell neoplasm
Beyond the preview
Go deeper on NCT04439331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439331.